Clinical Trial Detail

NCT ID NCT01125176
Title Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Lenalidomide + Rituximab + Thalidomide

Age Groups: senior adult

No variant requirements are available.